Bristol-Myers Squibb Company
Bristol-Myers Squibb Company BMY Peers
See (BMY) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BMY | $47.63 | +0.00% | 95.5B | 17.51 | $2.68 | +5.23% |
| LLY | $779.28 | +0.00% | 739.3B | 63.68 | $12.25 | +0.72% |
| AZN | $71.13 | +0.00% | 430.9B | 28.02 | $2.48 | +2.22% |
| JNJ | $155.56 | +0.00% | 375.4B | 17.35 | $8.99 | +3.22% |
| ABBV | $190.75 | +0.00% | 334.3B | 81.24 | $2.33 | +3.37% |
| NVO | $69.82 | +0.00% | 306.3B | 19.06 | $3.63 | +2.33% |
| NVS | $123.81 | +0.00% | 240.8B | 19.11 | $6.38 | +3.28% |
| MRK | $82.39 | +0.00% | 203.3B | 11.77 | $6.88 | +3.95% |
| AMGN | $296.85 | +0.00% | 160.5B | 27.19 | $10.98 | +3.10% |
| PFE | $25.32 | +0.00% | 144.4B | 18.40 | $1.38 | +6.69% |
Stock Comparison
BMY vs LLY Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, LLY has a market cap of 739.3B. Regarding current trading prices, BMY is priced at $47.63, while LLY trades at $779.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas LLY's P/E ratio is 63.68. In terms of profitability, BMY's ROE is +0.32%, compared to LLY's ROE of +0.77%. Regarding short-term risk, BMY is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs AZN Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, AZN has a market cap of 430.9B. Regarding current trading prices, BMY is priced at $47.63, while AZN trades at $71.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas AZN's P/E ratio is 28.02. In terms of profitability, BMY's ROE is +0.32%, compared to AZN's ROE of +0.19%. Regarding short-term risk, BMY is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs JNJ Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, JNJ has a market cap of 375.4B. Regarding current trading prices, BMY is priced at $47.63, while JNJ trades at $155.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas JNJ's P/E ratio is 17.35. In terms of profitability, BMY's ROE is +0.32%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, BMY is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs ABBV Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, ABBV has a market cap of 334.3B. Regarding current trading prices, BMY is priced at $47.63, while ABBV trades at $190.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas ABBV's P/E ratio is 81.24. In terms of profitability, BMY's ROE is +0.32%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, BMY is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs NVO Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, NVO has a market cap of 306.3B. Regarding current trading prices, BMY is priced at $47.63, while NVO trades at $69.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas NVO's P/E ratio is 19.06. In terms of profitability, BMY's ROE is +0.32%, compared to NVO's ROE of +0.81%. Regarding short-term risk, BMY is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs NVS Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, NVS has a market cap of 240.8B. Regarding current trading prices, BMY is priced at $47.63, while NVS trades at $123.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas NVS's P/E ratio is 19.11. In terms of profitability, BMY's ROE is +0.32%, compared to NVS's ROE of +0.31%. Regarding short-term risk, BMY is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs MRK Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, MRK has a market cap of 203.3B. Regarding current trading prices, BMY is priced at $47.63, while MRK trades at $82.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas MRK's P/E ratio is 11.77. In terms of profitability, BMY's ROE is +0.32%, compared to MRK's ROE of +0.38%. Regarding short-term risk, BMY is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs AMGN Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, AMGN has a market cap of 160.5B. Regarding current trading prices, BMY is priced at $47.63, while AMGN trades at $296.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas AMGN's P/E ratio is 27.19. In terms of profitability, BMY's ROE is +0.32%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, BMY is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs PFE Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, PFE has a market cap of 144.4B. Regarding current trading prices, BMY is priced at $47.63, while PFE trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas PFE's P/E ratio is 18.40. In terms of profitability, BMY's ROE is +0.32%, compared to PFE's ROE of +0.09%. Regarding short-term risk, BMY is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs GILD Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, GILD has a market cap of 139B. Regarding current trading prices, BMY is priced at $47.63, while GILD trades at $111.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas GILD's P/E ratio is 14.44. In terms of profitability, BMY's ROE is +0.32%, compared to GILD's ROE of +0.32%. Regarding short-term risk, BMY is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs SNY Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, SNY has a market cap of 117.6B. Regarding current trading prices, BMY is priced at $47.63, while SNY trades at $49.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas SNY's P/E ratio is 16.65. In terms of profitability, BMY's ROE is +0.32%, compared to SNY's ROE of +0.08%. Regarding short-term risk, BMY is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs CELG-RI Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, CELG-RI has a market cap of 96.9B. Regarding current trading prices, BMY is priced at $47.63, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.32%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, BMY is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs GSK Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, GSK has a market cap of 78.2B. Regarding current trading prices, BMY is priced at $47.63, while GSK trades at $38.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas GSK's P/E ratio is 18.72. In terms of profitability, BMY's ROE is +0.32%, compared to GSK's ROE of +0.22%. Regarding short-term risk, BMY is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs HZNP Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BMY is priced at $47.63, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BMY's ROE is +0.32%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BMY is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.
BMY vs BIIB Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, BIIB has a market cap of 19.5B. Regarding current trading prices, BMY is priced at $47.63, while BIIB trades at $133.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas BIIB's P/E ratio is 13.13. In terms of profitability, BMY's ROE is +0.32%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, BMY is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs GRFS Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, GRFS has a market cap of 7.6B. Regarding current trading prices, BMY is priced at $47.63, while GRFS trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas GRFS's P/E ratio is 33.63. In terms of profitability, BMY's ROE is +0.32%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, BMY is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs OGN Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, OGN has a market cap of 2.6B. Regarding current trading prices, BMY is priced at $47.63, while OGN trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas OGN's P/E ratio is 3.46. In terms of profitability, BMY's ROE is +0.32%, compared to OGN's ROE of +1.82%. Regarding short-term risk, BMY is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs CTOR Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, CTOR has a market cap of 378.5M. Regarding current trading prices, BMY is priced at $47.63, while CTOR trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas CTOR's P/E ratio is -13.92. In terms of profitability, BMY's ROE is +0.32%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, BMY is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs SCLX Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, SCLX has a market cap of 44.2M. Regarding current trading prices, BMY is priced at $47.63, while SCLX trades at $6.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas SCLX's P/E ratio is -0.42. In terms of profitability, BMY's ROE is +0.32%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, BMY is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs SCLXW Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, SCLXW has a market cap of 34.7M. Regarding current trading prices, BMY is priced at $47.63, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.32%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, BMY is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs MIRA Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, MIRA has a market cap of 20.3M. Regarding current trading prices, BMY is priced at $47.63, while MIRA trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas MIRA's P/E ratio is -2.49. In terms of profitability, BMY's ROE is +0.32%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, BMY is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs SRXH Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, SRXH has a market cap of 7.5M. Regarding current trading prices, BMY is priced at $47.63, while SRXH trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas SRXH's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.32%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, BMY is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.
BMY vs CRXT Comparison
BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 95.5B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BMY is priced at $47.63, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 17.51, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BMY's ROE is +0.32%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BMY is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.